Definition & Epidemiology
Acute heart failure (AHF) refers to the rapid onset or acute worsening of symptoms and/or signs of heart failure (HF), typically prompting urgent medical evaluation, emergency department (ED) visit, or hospitalization. It encompasses:
- Newly diagnosed HF, often due to myocardial infarction (MI), myocarditis, or toxic insults (e.g., chemotherapy).
- Acute decompensation of chronic HF, frequently triggered by identifiable precipitants.
Incidence: ~1–2 million hospitalizations/year in the U.S. Mortality remains high—30-day mortality ~10%, 1-year mortality ~25–30%—underscoring the need for rapid, guideline-directed intervention.
Pathophysiology & Clinical Presentation
AHF is primarily a syndrome of cardiac pump failure leading to elevated filling pressures (especially left ventricular end-diastolic pressure), resulting in:
- Cardiopulmonary congestion: Dyspnea (orthopnea, paroxysmal nocturnal dyspnea), fatigue, cough.
- Systemic hypoperfusion: Hypotension, oliguria, altered mental status, cool extremities—especially in cardiogenic shock.
The Frank-Starling mechanism is impaired; increased preload fails to augment stroke volume due to ventricular dysfunction or stiffness. In HFrEF (LVEF ≤40%), systolic impairment dominates; in HFpEF (LVEF ≥50%), diastolic dysfunction, elevated left atrial pressures, and vascular stiffening predominate—though acute decompensation can occur in either phenotype.
Evaluation: A Structured Diagnostic Approach
1. Clinical Suspicion & History
Suspect AHF in patients presenting with:
- Symptoms: New/worsening dyspnea (at rest or minimal exertion), fatigue, orthopnea, PND, cough.
- Signs: Jugular venous distension (JVD) >4 cm above sternal angle, S3 gallop (specificity ~80% for elevated LVEDP), pulmonary rales, peripheral edema, hepatojugular reflux.
Key precipitating factors (per Class I recommendations):
| Category | Examples |
|---|---|
| Cardiac | Acute coronary syndrome (ACS), arrhythmia (esp. atrial fibrillation with rapid ventricular response), acute valvular regurgitation (e.g., papillary muscle rupture post-MI), myocarditis, tachycardia-bradycardia syndrome |
| Non-cardiac | Nonadherence to medications/diet (Na⁺ restriction), renal impairment (acute kidney injury), uncontrolled hypertension, pulmonary embolism, COPD exacerbation, anemia, infection (e.g., pneumonia), substance use (cocaine, methamphetamine, heavy alcohol) |
| Iatrogenic | NSAIDs, thiazolidinediones, calcium channel blockers (verapamil/diltiazem), negative inotropes (e.g., verapamil in HFrEF) |
🔍 Red Flags for Non-HF Causes: Pleural effusion > ascites (more common in right HF); wheezing (cardiac asthma vs. COPD/asthma); focal neurological deficits (stroke mimicking AHF).
2. Laboratory Testing
| Test | Clinical Utility & Interpretation |
|---|---|
| BNP/NT-proBNP | • Diagnostic: NT-proBNP >300 pg/mL rules out HF (sensitivity 98%); >450 pg/mL (<50 y/o), >900 pg/mL (>50 y/o), >1800 pg/mL (>75 y/o) supports diagnosis • Prognostic: Levels >1000 pg/mL predict higher mortality and rehospitalization • Caveats: Elevated in renal failure (eGFR <60 mL/min), elderly, pulmonary embolism, sepsis; falsely low in obesity, atrial fibrillation |
| Troponin | Elevations suggest concurrent MI or myocardial injury (present in ~50% of AHF admissions); guides coronary evaluation |
| Lactate | >2 mmol/L indicates tissue hypoperfusion; persistent elevation predicts mortality in cardiogenic shock |
| CBC, CMP, LFTs, TSH, Urinalysis | Identify anemia (Hb <10 g/dL worsens HF), hyperthyroidism/hypothyroidism, hepatorenal syndrome, urinary tract infection |
| Serum electrolytes (especially Mg²⁺) | Hypomagnesemia potentiates diuretic resistance and arrhythmias |
3. Electrocardiography (ECG)
- Class I indication: Essential to detect:
- ACS (ST elevation/depression, T-wave inversion)
- Arrhythmias: AFib (most common in AHF; HR >150 bpm reduces cardiac output), VT, bradyarrhythmias
- LVH, conduction delays (e.g., LBBB—may indicate CRT eligibility)
- BNP interpretation: ECG changes of ischemia + elevated troponin → urgent catheterization.
4. Imaging
| Modality | Indications & Key Findings |
|---|---|
| Chest X-ray (CXR) | • Pulmonary congestion: Kerley B lines, bat-wing opacities • Cardiomegaly (cardiothoracic ratio >50%) • Pleural effusions (bilateral = HF; unilateral = consider PE) • Normal CXR does NOT exclude AHF (sensitivity ~60–70%) |
| Transthoracic Echocardiography (TTE) | • Class I recommendation in initial evaluation: – LVEF (categorize as HFrEF, HFmrEF, HFpEF) – Wall motion abnormalities (ischemic vs. non-ischemic cardiomyopathy) – Valve function (especially acute MR/LR regurgitation) – Diastolic parameters (E/e′, LA volume index, TR jet velocity for pulmonary pressure) – RV size/function (predicts mortality in AHF) • Point-of-care ultrasound (POCUS): Rapid assessment of LV function, IVC collapsibility, lung B-lines |
| Advanced Imaging | • Cardiac MRI: Gold standard for LVEF, tissue characterization (fibrosis in DCM, amyloidosis), viability assessment • CT Angiography: If PE or aortic dissection suspected; coronary CT angiography if low-intermediate pretest probability of CAD • Radionuclide ventriculography (MUGA): Alternative to MRI for LVEF quantitation |
| Coronary Angiography | Indicated in AHF with hemodynamic instability, ACS features, or high suspicion of ischemic etiology—especially if eligible for revascularization |
📌 Note: HFpEF accounts for ~50% of AHF admissions. TTE may show normal LVEF but abnormal diastolic function (E/e′ >14, LA enlargement >34 mL/m², TR velocity >2.8 m/s).
Management: Integrating Guidelines & Recent Evidence
I. Initial Resuscitation & Hemodynamic Stabilization
A. Oxygen Therapy
- Class I: Administer if SpO₂ <90% or PaO₂ <60 mmHg.
- Avoid routine oxygen in normoxemic patients—may cause vasoconstriction and worsen outcomes (ORBITA-HF subgroup analysis).
B. Diuresis for Volume Overload
- IV loop diuretics remain first-line for decongestion (Class I).
- Naïve to loop diuretics: Furosemide 20–40 mg IV bolus; max 80 mg if severe congestion or CKD.
- On chronic oral diuretics: Convert using equianalgesic dosing:
- Furosemide 40 mg PO ≈ Bumetanide 1 mg PO ≈ Torsemide 20 mg PO
→ Initiate IV furosemide at 2× the total daily oral equivalent dose (e.g., furosemide 80 mg IV if on 40 mg PO daily).
- Furosemide 40 mg PO ≈ Bumetanide 1 mg PO ≈ Torsemide 20 mg PO
- Administer over 1–2 min for rapid effect; consider continuous infusion if severe congestion (e.g., 5–10 mg/h).
🧪 Monitoring diuretic response:
- Early diuresis (>2 L/day in first 48h) correlates with improved outcomes.
- Diuretic resistance: Defined as urine output <3 L/24h despite furosemide >80 mg IV daily. Mechanisms include tubular resistance, neurohormonal activation, NSAID use.
Adjuvant Diuretic Strategies (Class IIb):
- Add metolazone (2.5–5 mg/day) or chlorthalidone—not thiazides (shorter half-life): Avoids potassium wasting but monitor for hypotension and azotemia.
- Acetazolamide: Carbonic anhydrase inhibitor; may enhance diuresis in refractory cases, but limited evidence (small RCTs: RED-HF substudy).
- Avoid combinations with potassium-sparing diuretics alone—high risk of hyperkalemia.
C. Vasodilators
- IV nitroglycerin: Preferred in AHF with systolic BP ≥110 mmHg; reduces preload and afterload. Dose: 5–200 µg/min titrated to BP.
- IV nitroprusside: For severe hypertension or cardiogenic shock (BP <90 mmHg); monitor for cyanide toxicity if >2 µg/kg/min × >24h.
- Evidence: ORANGE-HF trial showed net clinical benefit with early vasodilator use in normotensive AHF.
D. Noninvasive Ventilation (NIV)
- Class IIa recommendation: For respiratory rate >25 bpm, SpO₂ <90% on room air, or work of breathing distress.
- CPAP: Improves oxygenation in pulmonary edema.
- BiPAP: Better tolerance; reduces intubation risk (NIV-AHF meta-analysis: OR 0.47 for intubation).
- Avoid NIV in hypotension (SBP <90 mmHg) or altered mental status.
II. Advanced Hemodynamic Monitoring
- Pulmonary artery catheter (PAC):
- Class IIb: Consider if diagnostic uncertainty persists (e.g., distinguishing HF from renal failure), or in refractory cases.
- Guidelines (2022 AHA/ACC/HFSA): Not routinely recommended; may guide therapy in complex cases but associated with higher complication rates without mortality benefit (FOCUS, ADHERE subanalyses).
III. Ultrafiltration & Vaptans
- Ultrafiltration:
- Class IIb: Reserved for diuretic-resistant congestion with worsening renal function.
- CARRESS-HF and ADHERE-UF trials: No superior decongestion vs. pharmacotherapy; higher rates of acute kidney injury and bleeding.
- Vaptans (e.g., tolvaptan):
- Class IIb: Only for hyponatremia (Na⁺ <130 mmol/L) with volume overload; avoid in euvolemic/hypernatremic states.
- SALTWRITER trial: Rapid correction of sodium without osmotic demyelination.
IV. Inotropic Support
- Indications: SBP <90 mmHg + signs of hypoperfusion (e.g., cool extremities, oliguria, lactic acidosis) unresponsive to fluid challenge.
- Drugs:
- Dobutamine: First-line inotrope; 2–15 µg/kg/min. Avoid in tachyarrhythmias.
- Milrinone: PDE3 inhibitor; adds vasodilation—caution in renal impairment.
- Levosimendan (not FDA-approved): Calcium sensitizer; better tolerability in European trials (LUSTRAL).
- Vasopressors (e.g., norepinephrine): For profound hypotension with relative bradycardia.
⚠️ Inotropes increase mortality in stable HF—use only for short-term hemodynamic support (<24–48h), bridging to MCS or transplant.
V. Thromboembolism Prophylaxis
- Class I: LMWH (e.g., enoxaparin 40 mg SC daily) in immobile patients without contraindications.
- Rationale: AHF increases venous stasis; incidence of VTE ~5% in hospitalized HF.
Post-Stabilization Management: Guideline-Directed Medical Therapy (GDMT)
The 2022 AHA/ACC/HFSA Guidelines emphasize early initiation and rapid uptitration of GDMT before discharge to reduce rehospitalization/mortality:
| Therapy | Evidence Base | Key Recommendations |
|---|---|---|
| ARNI (sacubitril/valsartan) | PARADIGM-HF: 20% ↓ in CV death/HF hospitalization vs. enalapril | Preferred over ACEi/ARB for HFrEF (LVEF ≤40%) if SBP ≥100 mmHg. Start at 24/26 mg BID; upTitrate to 97/103 mg BID. Hold ACEi 36h prior. |
| SGLT2 Inhibitors ( dapagliflozin, empagliflozin) | DAPA-HF, EMPEROR-Reduced: ↓ HF hospitalizations by 30% regardless of diabetes status | Start early—even in outpatient setting. Monitor for euglycemic DKA (rare). |
| Beta-blockers | COPERNICUS (carvedilol), MERIT-HF (metoprolol succinate), CIBIS-II (bisoprolol) | Initiate at low dose during hospitalization if euvolemic and SBP ≥100 mmHg; uptitrate every 2 weeks. Avoid in acute decompensated HF with cardiogenic shock. |
| MRAs (spironolactone, eplerenone) | RALES, EMPHASIS-HF: ↓ mortality by 30% in severe HFrEF | Monitor K⁺ and Cr; avoid if eGFR <30 mL/min/1.73m² or K⁺ >5.0 mmol/L. |
| ACEi/ARB | SOLVD, CHARM: Mortality benefit in HFrEF | Use if ARNI not tolerated (e.g., angioedema). |
📌 Critical Action: Discharge with a transition plan—follow-up within 7 days, medication reconciliation, and telehealth check-ins. Early outpatient HF clinic involvement ↓ readmissions by 25% (ADHERE data).
Differential Diagnosis: Key Considerations
| Condition | Clues Distinguishing from AHF | Diagnostic Test |
|---|---|---|
| COPD/Asthma exacerbation | Wheezing, history of smoking, chronic sputum; no S3 or JVD | Spirometry (post-bronchodilator FEV₁/FVC <0.7) |
| Pulmonary embolism | Pleuritic chest pain, tachycardia, RV strain on ECG | D-dimer → CT angiography if high probability |
| Acute myocarditis | Recent viral illness, elevated troponin, normal coronaries | Cardiac MRI (late gadolinium enhancement) |
| Renal failure with volume overload | Pre-existing CKD, no cardiac risk factors; echocardiogram shows preserved EF | Urinalysis (bland sediment vs. dysmorphic RBCs) |
Conclusion: Clinical Pearls
- BNP/NT-proBNP:
- NT-proBNP >300 pg/mL rules in HF; >1800 pg/mL in acute setting strongly supports diagnosis.
- False negatives: obesity, ACS, atrial fibrillation; false positives: renal failure, pulmonary hypertension.
- Diuretic Resistance:
- Define as urine output <150 mL/h after 4 hours of IV furosemide ≥80 mg/day OR weight loss <0.5 kg/day.
- Solutions: intermittent bolus infusion (e.g., furosemide 40 mg IV q6h), combined diuretic therapy (loop + metolazone 2.5–5 mg daily).
- Ejection Fraction Reassessment:
- Transthoracic echo must be performed within 48h of admission to guide therapy.
- If echo suboptimal, CMR provides superior tissue characterization (e.g., fibrosis in non-ischemic cardiomyopathy).
- SGLT2 Inhibitors Are Game-Changers:
- Benefit in HFrEF and HFpEF (DELIVER, EMPEROR-Preserved), starting early improves outcomes.
This integrated approach—rooted in latest ACC/AHA/HFSA guidelines and pivotal trials—optimizes hemodynamic stability while laying the foundation for long-term mortality reduction. Always individualize therapy based on comorbidities (e.g., avoid ACEi in bilateral renal artery stenosis).
Sources: 2022 AHA/ACC/HFSA Guideline for Heart Failure, ESC Guidelines 2023, Cochrane Database Syst Rev 2021; JACC 2023; NEJM PARADIGM-HF, DAPA-HF, EMPEROR-Reduced.
